AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26743498 — intervention group
Group type: EXPERIMENTAL
Intervention: NIRS-visible group (crSO2 monitoring)
Number of subjects: 60
Study 26743498 — intervention group
Group type: COMPARATOR
Intervention: NIRS-not-visible group (only pulse oximetry)
Number of subjects: 60
Study 23435350 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational Music Making (RMM)
Number of subjects: 34
Study 23435350 — intervention group
Group type: COMPARATOR
Intervention: Quiet reading
Number of subjects: 34
Study 21671126 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin
Number of subjects: 50
Study 18340278 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 mug/day)
Number of subjects: 61
Study 18340278 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (50 mug/day) plus medroxyprogesterone acetate (5 mg/day)
Number of subjects: 61
Study 18340278 — intervention group
Group type: COMPARATOR
Intervention: Oral estradiol (2 mg/day)
Number of subjects: 61
Study 16426255 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 60
Study 16426255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 60
Study 16426255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12940397 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training
Number of subjects: 285
Study 12940397 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic Stress Inoculation Training
Number of subjects: 285
Study 12940397 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonhypnotic analgesia suggestions
Number of subjects: 285
Study 12940397 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia suggestions
Number of subjects: 285
Study 12940397 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic induction treatment
Number of subjects: 285
Study 12940397 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 285
Study 10901102 — intervention group
Group type: EXPERIMENTAL
Intervention: Gd-DTPA-BMEA (OptiMARK)
Number of subjects: 395
Study 10901102 — intervention group
Group type: COMPARATOR
Intervention: Gd-DTPA (Magnevist)
Number of subjects: 395
Study 9358478 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated IPGs
Number of subjects: 39
Study 9358478 — intervention group
Group type: COMPARATOR
Intervention: Uncoated IPGs
Number of subjects: 39
Study 1589071 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg clebopride administered iv after surgery
Number of subjects: 40
Study 1589071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 3803414 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral verapamil (Isoptin) b.d. or t.d.s. (240, 360 or 480 mg daily)
Number of subjects: 12
Study 30068784 — intervention group
Group type: EXPERIMENTAL
Intervention: T-stenting
Number of subjects: 238
Study 30068784 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-crush
Number of subjects: 238
Study 30068784 — intervention group
Group type: EXPERIMENTAL
Intervention: Culotte
Number of subjects: 238
Study 27759644 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycontin and gabapentin
Number of subjects: 60
Study 27759644 — intervention group
Group type: COMPARATOR
Intervention: Oxycontin and placebo
Number of subjects: 60
Study 24495617 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide (1mg daily sc injections for 4 days in the 1st and 3rd weeks)
Number of subjects: 0
Study 24495617 — intervention group
Group type: COMPARATOR
Intervention: Nandrolone decanoate (ND) co-administration
Number of subjects: 0
Study 24495617 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine leuprolide and M1 measurement
Number of subjects: 0
Study 24495617 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening using urine steroid and LH measurements
Number of subjects: 0
Study 23210198 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticotomy-facilitated orthodontic tooth movement (CFO)
Number of subjects: 20
Study 23210198 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthodontic therapy
Number of subjects: 20
Study 20671206 — intervention group
Group type: COMPARATOR
Intervention: Individualized oral hygiene instruction (OHI)
Number of subjects: 306
Study 20671206 — intervention group
Group type: EXPERIMENTAL
Intervention: OHI and applications of 1% chlorhexidine varnish every 3 months
Number of subjects: 306
Study 20671206 — intervention group
Group type: EXPERIMENTAL
Intervention: OHI and applications of 5% sodium fluoride varnish every 3 months
Number of subjects: 306
Study 20671206 — intervention group
Group type: EXPERIMENTAL
Intervention: OHI and annual applications of 38% silver diamine fluoride (SDF) solution
Number of subjects: 306
Study 19007071 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 tapered gutta‐percha using System B for downpack and Obtura II for backfilling
Number of subjects: 40
Study 19007071 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06 tapered gutta‐percha using System B for downpack and Obtura II for backfilling
Number of subjects: 40
Study 18701006 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual specific immunotherapy (SLIT), treated daily for at least two consecutive years.
Number of subjects: 305
Study 18701006 — intervention group
Group type: COMPARATOR
Intervention: Control group (never treated with specific immunotherapy).
Number of subjects: 305
Study 15155200 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release (XR) formulation of ciprofloxacin (1,000 mg/day)
Number of subjects: 0
Study 15155200 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) formulation of ciprofloxacin (1,000 mg/day)
Number of subjects: 0
Study 15155200 — intervention group
Group type: COMPARATOR
Intervention: Comparison of XR and IR formulations at MIC of 0.5 mg/liter
Number of subjects: 0
Study 15155200 — intervention group
Group type: COMPARATOR
Intervention: Comparison of XR and IR formulations at MICs of 0.03 and 2.0 mg/liter
Number of subjects: 0
Study 11465169 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional antibiotic prophylaxis (ceftriaxone 2 g on postoperative day 1)
Number of subjects: 500
Study 11465169 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged antibiotic prophylaxis (ticarcillin + clavulanic acid 3 x 5.2 g during 72 hours)
Number of subjects: 500
Study 11465169 — intervention group
Group type: COMPARATOR
Intervention: Untreated positive patients
Number of subjects: 500
Study 11465169 — intervention group
Group type: COMPARATOR
Intervention: Untreated negative patients
Number of subjects: 500
Study 9236440 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg IV (n = 15)
Number of subjects: 20
Study 9236440 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline (n = 5)
Number of subjects: 20
Study 8232945 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (600, 1,200, or 1,800 mg/d)
Number of subjects: 306
Study 8232945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 8232945 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 306
Study 3631784 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (10 micrograms/m2)
Number of subjects: 35
Study 30582774 — intervention group
Group type: EXPERIMENTAL
Intervention: INS/DAPA (Insulin + Dapagliflozin 5 mg/day)
Number of subjects: 18
Study 30582774 — intervention group
Group type: COMPARATOR
Intervention: INS (Basal-bolus insulin titration algorithm)
Number of subjects: 18
Study 30582774 — intervention group
Group type: EXPERIMENTAL
Intervention: INS/DAPA
Number of subjects: 18
Study 30582774 — intervention group
Group type: COMPARATOR
Intervention: INS
Number of subjects: 18
Study 28432077 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month, 3×/week aerobic training
Number of subjects: 21
Study 28432077 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 21
Study 27103371 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoglycemia for 4h
Number of subjects: 15
Study 27103371 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion for 4h
Number of subjects: 15
Study 27103371 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of normoglycemia and GLP-1 for 4h
Number of subjects: 15
Study 27103371 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemia plus GLP-1 infusion for 4h
Number of subjects: 15
Study 25579357 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% eye drops once daily for 4 weeks
Number of subjects: 40
Study 25579357 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine 0.2% eye drops twice daily for 4 weeks
Number of subjects: 40
Study 21722178 — intervention group
Group type: EXPERIMENTAL
Intervention: ESD with a balloon wedged in the bulbus duodeni (balloon [+] group)
Number of subjects: 16
Study 21722178 — intervention group
Group type: COMPARATOR
Intervention: Conventional ESD with no balloon (balloon [-] group)
Number of subjects: 16
Study 19996339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation solution (TIS) 300 mg/5 ml twice daily for 28 days
Number of subjects: 88
Study 19996339 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation solution (TIS) 300 mg/5 ml twice daily for 56 days
Number of subjects: 88
Study 19996339 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS) 300 mg/5 ml twice daily for 28 days (control group)
Number of subjects: 88
Study 17934393 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/d
Number of subjects: 0
Study 16371799 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthesia and balance exercises in addition to strengthening exercises
Number of subjects: 66
Study 16371799 — intervention group
Group type: COMPARATOR
Intervention: Strengthening exercises only
Number of subjects: 66
Study 12088975 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 5 mg IV
Number of subjects: 120
Study 12088975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 2 mg IV
Number of subjects: 120
Study 12088975 — intervention group
Group type: COMPARATOR
Intervention: Saline (Placebo)
Number of subjects: 120
Study 10218187 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy dog
Number of subjects: 0
Study 8574128 — intervention group
Group type: EXPERIMENTAL
Intervention: Clemastine fumarate
Number of subjects: 0
Study 8574128 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 2669440 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg moclobemide
Number of subjects: 62
Study 2669440 — intervention group
Group type: COMPARATOR
Intervention: 150 mg clomipramine
Number of subjects: 62
Study 1095963 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe) intravenously administered for 20 days at two daily doses of 15 mg
Number of subjects: 70
Study 1095963 — intervention group
Group type: COMPARATOR
Intervention: Fructose-1-6-diphosphate sodium salt intravenously administered for 20 days at two daily doses of 2.5 mg
Number of subjects: 70
Study 30616009 — intervention group
Group type: EXPERIMENTAL
Intervention: MultiPoint Pacing (MPP) programmed to mandated MPP‐AS settings
Number of subjects: 5000
Study 30616009 — intervention group
Group type: COMPARATOR
Intervention: Continued BiV pacing
Number of subjects: 5000
Study 28679495 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine containing 120 μg sF with 5 μg GLA in SE
Number of subjects: 261
Study 28679495 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine containing 120 μg sF with 2.5 μg GLA in SE
Number of subjects: 261
Study 28679495 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine containing 80 μg sF with 2.5 μg GLA in SE
Number of subjects: 261
Study 28679495 — intervention group
Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 261
Study 28679495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 26522175 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE Healthy Lifestyles TEEN Program
Number of subjects: 779
Study 26522175 — intervention group
Group type: COMPARATOR
Intervention: Healthy Teens (attention control program)
Number of subjects: 779
Study 23003920 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical stripping
Number of subjects: 35
Study 23003920 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (180 mJ, 10 Hz, long pulse)
Number of subjects: 35
Study 23003920 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser (2 to 4 W, continuous wave)
Number of subjects: 35
Study 23003920 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser
Number of subjects: 35
Study 23003920 — intervention group
Group type: COMPARATOR
Intervention: Comparison of all treatments
Number of subjects: 35
Study 22003347 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithmic internet-based intervention alone
Number of subjects: 171
Study 22003347 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithmic internet-based intervention in combination with a prescribed bedtime routine
Number of subjects: 171
Study 22003347 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 171
Study 19322730 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 19322730 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 17578981 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA with ropivacaine and sufentanil
Number of subjects: 68
Study 17578981 — intervention group
Group type: COMPARATOR
Intervention: IV morphine
Number of subjects: 68
Study 15628811 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 421
Study 15628811 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 421
Study 15159244 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA-triacylglycerol
Number of subjects: 180
Study 15159244 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA-FFA
Number of subjects: 180
Study 15159244 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA (both groups)
Number of subjects: 180
Study 15159244 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 180
Study 11176493 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous sacral nerve root neuromodulation
Number of subjects: 15
Study 9403147 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional information (high or low in distinctiveness, consistency, and consensus)
Number of subjects: 0
Study 9403147 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study 8501476 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive follow-up (pulmonary disease screening and follow-up at 3-month intervals)
Number of subjects: 1353
Study 8501476 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up (6-month follow-up intervals with annual screening)
Number of subjects: 1353
Study 3689629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 11
Study 3689629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 11
Study 3689629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 11
Study 3689629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 28659349 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Mucosal Resection (EMR)
Number of subjects: 204
Study 28659349 — intervention group
Group type: COMPARATOR
Intervention: Transanal Endoscopic Microsurgery (TEM)
Number of subjects: 204
Study 26813677 — intervention group
Group type: EXPERIMENTAL
Intervention: G.H.3. tablets
Number of subjects: 100
Study 26813677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 25895695 — intervention group
Group type: EXPERIMENTAL
Intervention: Thylakoids
Number of subjects: 0
Study 23083925 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.04 mg/kg) administered at peak exercise during session #2
Number of subjects: 38
Study 20813357 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 2 embryo transfer
Number of subjects: 0
Study 20813357 — intervention group
Group type: COMPARATOR
Intervention: Day 3 embryo transfer
Number of subjects: 0
Study 18199797 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 16
Study 18199797 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 16
Study 17023713 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg DHA + 150 mg eicosapentaenoic acid, 400 microg 5‐methyl‐tetrahydrofolic acid
Number of subjects: 136
Study 17023713 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg DHA + 400 microg 5‐methyl‐tetrahydrofolic acid
Number of subjects: 136
Study 17023713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 12931301 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal electrical cardioversion using epicardial wire electrodes with low shock energies
Number of subjects: 2
Study 12931301 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (antiarrhythmic medication, calcium channel antagonists, beta-adrenergic blockers, or amiodarone)
Number of subjects: 2
Study 12931301 — intervention group
Group type: COMPARATOR
Intervention: External electrical cardioversion under general anesthesia
Number of subjects: 2
Study 10658028 — intervention group
Group type: EXPERIMENTAL
Intervention: Poikilocapnic hypoxia (PH)
Number of subjects: 13
Study 10658028 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (IH)
Number of subjects: 13
Study 10658028 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoxic voluntary hyperpnea (HP)
Number of subjects: 13
Study 10658028 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (NO)
Number of subjects: 13
Study 8638778 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (200,000 KIU/h)
Number of subjects: 44
Study 8638778 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 44
Study 1446868 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT emulsion (50%/50%)
Number of subjects: 35
Study 1446868 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT emulsion
Number of subjects: 35
Study 1446868 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose in NaCl 0.9% (Control)
Number of subjects: 35
Study 6423840 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-field pelvic radiation
Number of subjects: 73
Study 6423840 — intervention group
Group type: COMPARATOR
Intervention: Delayed hormonal therapy
Number of subjects: 73
Study 30520764 — intervention group
Group type: EXPERIMENTAL
Intervention: Serrated polyposis syndrome (SPS) diagnosis
Number of subjects: 5000
Study 30520764 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasons for missed SPS diagnosis
Number of subjects: 5000
Study 29061179 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation
Number of subjects: 60
Study 29061179 — intervention group
Group type: COMPARATOR
Intervention: Weight-loss diet
Number of subjects: 60
Study 25538172 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline neutrophil-lymphocyte ratio (BLNLR) ≥3.0
Number of subjects: 755
Study 25538172 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion from high (≥3) to low (<3) NLR
Number of subjects: 755
Study 25538172 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NLR (BLNLR)
Number of subjects: 755
Study 25538172 — intervention group
Group type: EXPERIMENTAL
Intervention: Median OS
Number of subjects: 755
Study 23656766 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous high-volume hemofiltration (CHVHF)
Number of subjects: 65
Study 20833386 — intervention group
Group type: EXPERIMENTAL
Intervention: sidelying end‐range lumbar flexion position
Number of subjects: 41
Study 20833386 — intervention group
Group type: EXPERIMENTAL
Intervention: sidelying mid‐range lumbar flexion position
Number of subjects: 41
Study 19492924 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient induction using nitric oxide donors
Number of subjects: 0
Study 19492924 — intervention group
Group type: COMPARATOR
Intervention: Inpatient induction
Number of subjects: 0
Study 19492924 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient cervical ripening by prostaglandins or other cervical ripening agents
Number of subjects: 0
Study 17562243 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib/gemcitabine
Number of subjects: 100
Study 17562243 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib/erlotinib
Number of subjects: 100
Study 17562243 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib/gemcitabine or sorafenib/erlotinib
Number of subjects: 100
Study 15062911 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education
Number of subjects: 30
Study 12147029 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmodified whole-blood-derived platelets
Number of subjects: 66
Study 12147029 — intervention group
Group type: EXPERIMENTAL
Intervention: Poststorage plasma-removed platelets
Number of subjects: 66
Study 12147029 — intervention group
Group type: COMPARATOR
Intervention: Prestorage WBC-reduced platelets
Number of subjects: 66
Study 10211515 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical bowel confinement (clear liquid diet with loperamide 4 mg three times per day and codeine phosphate 30 mg four times per day until the third postoperative day)
Number of subjects: 54
Study 10211515 — intervention group
Group type: COMPARATOR
Intervention: Regular diet (beginning the day of surgery)
Number of subjects: 54
Study 10211515 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical bowel confinement
Number of subjects: 54
Study 10211515 — intervention group
Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 54
Study 7789055 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural estradiol (0.05 mg/day) for 6 months
Number of subjects: 40
Study 7789055 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural estradiol (0.05 mg/day) and medroxyprogesteron acetate (10 mg/day) for 6 months
Number of subjects: 40
Study 7789055 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 40
Study 2290770 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication education program
Number of subjects: 0
Study 2290770 — intervention group
Group type: COMPARATOR
Intervention: Dummy intervention (control group)
Number of subjects: 0